Navigation Links
St. Francis Surgeon Uses Tissue Regeneration Technology to Rebuild Patients' Heart Structures
Date:7/8/2009

INDIANAPOLIS, July 8 /PRNewswire/ -- A surgeon at the St. Francis Heart Center is using a revolutionary technology that allows patients to rebuild their own cardiovascular tissue.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090708/DE43062LOGO-a )

(Logo: http://www.newscom.com/cgi-bin/prnh/20090708/DE43062LOGO-b )

Marc Gerdisch, M.D., is using the CorMatrix Extracellular Matrix (ECM)(TM) to modify and repair cardiac structures, allowing heart tissue to re-grow inside the beating hearts of heart surgery patients. The CorMatrix ECM is a unique biomaterial that harnesses the body's innate ability to repair damaged heart tissue. Over time, it is replaced by the patients' own tissue.

"The use of this biomaterial is a major advancement in cardiac surgery and allows us to provide our patients with restoration of normal anatomic structures. It opens the door to a new level of cardiac tissue reconstruction," said Gerdisch, director of cardiothoracic surgery at the St. Francis Heart Center and a partner at Cardiac Surgery Associates.

In August 2007, Gerdisch, who specializes in complex heart valve surgery, became the first in the world to apply this technology inside the heart, repairing a congenital defect.

"Similar uses of the ECM followed, at our and other institutions," reported Gerdisch, who is co-director of the St. Francis Midwest Heart Valve Center
'/>"/>

SOURCE St. Francis Heart Center
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
2. TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
3. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
4. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
5. Surgeons Find That Laparoscopic Banding Procedure Helps Overweight Adolescents Lose Weight and Improve Health
6. Surgeons Develop Innovative Life-Saving Treatments to Correct Massive Bleeding in Trauma Patients
7. Miami Plastic Surgeon Offers Hope to Acne Scarred Patients
8. Got Fat?: Plastic Surgeons Review Fat-Melting and Fat-Grafting Procedures
9. Legacy Good Samaritan Hospital Surgeons Find BSGI Effective in Determining Extent of Breast Cancer in Patients With Known Diagnosis
10. NJ-Based Surgeon Helps Pioneer Dramatic Advance in Treating Damaged Discs
11. Surgeon Generals Call to Action to Prevent DVT/PE Praised by NATT as Turning Point

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...wire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Na... the third quarter ended September 30, 2009. ,,...on stockholders in the third quarter of 2009 of $3... loss allocable to common stockholders in the thir...hare, and a net loss allocable to common stockhold...
(Date:11/9/2009)...re/ -- Groundbreaking articles in current issues o...time explore, in depth, the emergence of cannabino...ers and its potential benefits for patients. ,,...gton authors, Sunil Aggarwal, PhD who is a member ...ram and who conducted the article,s research and G...
(Date:11/9/2009)...re/ -- Celling Technologies, a subsidiary of Spine...is, Inc. to research potential applications for ad... acquired the global rights in spine for Tissue Ge...nology in November of 2007. Replacing the prior a...lling Technologies to further research adipose tis...
Breaking Medicine Technology:Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 2Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 3Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 4Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 5Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 6Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 7Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 8Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 9Medicinal Use of Marijuana: Past, Present and Future...A Fresh Look by Experts in the Field 2Celling Technologies Signs Exclusive Agreement to Research and Develop Adipose Tissue Stem Cell Technology in Regenerative Medicine Institutes 2Celling Technologies Signs Exclusive Agreement to Research and Develop Adipose Tissue Stem Cell Technology in Regenerative Medicine Institutes 3HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A 28H1N1 29 12381 1HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A 28H1N1 29 12381 2HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A 28H1N1 29 12381 3HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A 28H1N1 29 12381 4Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting 4502 1Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting 4502 2Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting 4502 3Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting 4502 4Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting 4502 5Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting 4502 6Keryx Biopharmaceuticals Announces Positive Data from a Randomized Multi Center Placebo Controlled Phase 2 Combination Study of KRX 0401 28Perifos 4500 1Keryx Biopharmaceuticals Announces Positive Data from a Randomized Multi Center Placebo Controlled Phase 2 Combination Study of KRX 0401 28Perifos 4500 2Keryx Biopharmaceuticals Announces Positive Data from a Randomized Multi Center Placebo Controlled Phase 2 Combination Study of KRX 0401 28Perifos 4500 3Keryx Biopharmaceuticals Announces Positive Data from a Randomized Multi Center Placebo Controlled Phase 2 Combination Study of KRX 0401 28Perifos 4500 4Keryx Biopharmaceuticals Announces Positive Data from a Randomized Multi Center Placebo Controlled Phase 2 Combination Study of KRX 0401 28Perifos 4500 5Keryx Biopharmaceuticals Announces Positive Data from a Randomized Multi Center Placebo Controlled Phase 2 Combination Study of KRX 0401 28Perifos 4500 6
...sdaq: TELK ) reported positive preclinical data f...ecule inhibitors of validated cancer targets,inclu...ented today at the,AACR-NCI-EORTC Conference on Mo...ncisco. Aurora kinases are enzymes that play a ke...-expressed in many human cancers, including breast...
...., a,privately held biopharmaceutical company deve...cular biomarker data demonstrating the overexpress...in in multiple cancers,including ovarian, breast a...ation of PARP overexpression in specific types of ...inical development of the company,s,pipeline of PA...
Other Medicine Technology:Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2 2BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types 2
(Date:11/9/2009)... formation could boost self-esteem, researchers sa... Autistic children are more likely to have handwri...than those without autism, researchers say. , T...alf of the study participants had autism spectrum ...e normal range for perceptual reasoning on an IQ t...
(Date:11/9/2009)...v. 9 /PRNewswire-FirstCall/ - Hard To Treat Diseas...y that Novartis, a US$41 billion international hea..., H1N1 Vaccine partner, Zhejiang Tianyuan Bio-Phar... of Switzerland will begin a five-year, $1 billion...dramatically increase its investment in its China ...
(Date:11/9/2009)... New study highlights positive influence of sports... Rosemont, IL (Vocus) November 9, 2009 -- As...reases. Recent research has highlighted the import...revent these issues. However, a new study publishe...: A Multidisciplinary Approach reveals that there...
(Date:11/9/2009)...mes 2010 National Ambassador ,, WHITE PLAINS,...ffman of Weston, Fla., was born so early and with ...ot say whether he would survive -- or if he would ...d was named March of Dimes 2010 National Ambassado..."My first minutes of motherhood and I was complete...
(Date:11/9/2009)...people went from incapacitated to working again, ... Electrical stimulation of a certain area of the b...epression, say German researchers. , They impla...he brains of 10 people. This area of the brain is...e remember good experiences and puts them in a sta...
Breaking Medicine News(10 mins):Health News:Handwriting Skills May Lag in Kids With Autism 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4Health News:High Impact Sports Participation May Improve Bone Mineral Density in Mature Athletes 2Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 2Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 3Health News:Brain Stimulation May Ease Treatment-Resistant Depression 2
...SSEN, Netherlands, May 7 Health ingredients Europ...food & beverage trade show, has been shortlist...est Trade Show Over 2000m2 Award, announced UBM In...ought together 7328 attendees with 450 exhibitors....
...e leader of dementia research in CSIRO,s Preventat...a Szoeke, says the report highlights the challenge...rs predicted to double to 465,000 by 2030. , "Abo...is crisis more effectively." , "By the time suffe...
...g Adults with AD/HD Make a Visit to the Halls of C...rce and Funding for the Mental Health Disorder , ...ll mark the fourth annual national Children,s Ment...ty Disorder (CHADD) and the American Academy of Ch...
...erence Call to Follow Release , , DENVER, May 7 ...the "Company") (OTC Bulletin Board: GLOB), an inte...y, will report its first quarter financial results... http://www.newscom.com/cgi-bin/prnh/20040226/GLO...
...ADELPHIA, May 7 Major League Baseball (MLB) has s...mask legal but banned substances for multi-million...estruction of the game as we know it. Sports team ...fine how the game should be run. , , "MLB is set ...
...ESTER, N.Y., May 7 Recent scientific studies publ...cinogenesis, Oncology, British Journal of Urology,... food extracts Quercetin, EGCG, Glycyrrhizin, and ...nding formulation. Gene-Eden was introduced in Feb...
Other Medicine News:Health News:Health ingredients Europe Shortlisted for AEO's Best Trade Show Over 2000m2 Award 2Health News:Dementia: Early detection is key 2Health News:The New Face of AD/HD Comes to Capitol Hill 2Health News:Global Med Technologies(R), Inc. to Report First Quarter Financial Results on Friday, May 15, 2009 2Health News:Global Med Technologies(R), Inc. to Report First Quarter Financial Results on Friday, May 15, 2009 3Health News:Is Bailout of Major League Baseball Next? Book Explains How Baseball Like Big Businesses Will Fail 2Health News:The Center for the Biology of Chronic Disease Highlights Anti-Cancer Activities of the Food Extracts Quercetin, EGCG, Glycyrrhizin, and Trans-Cinnamaldehyde 2
Neuro-Cool™ Cool Head Wrap
...noWELL Mycoplasma Pneumoniae Antibody (IgG) Test i...the detection of clinically significant IgG antibo...nt human serum specimens. The test should not be u...ycoplasma Pneumoniae Antibody (IgM) Test and is no...
ImmunoDOT Mono M Test
...noWELL VCA IgG Test is an ELISA method for the qua... Virus viral capsid antigen (VCA) in human serum. ...other testing such as the EBV nuclear antigen (EBN...heterophile tests, the results can serve as an aid...
Medicine Products: